De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Pertuzumab/trastuzumab (Primary) ; Docetaxel; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms DECRESCENDO
Most Recent Events
- 02 Dec 2024 Status changed from suspended to discontinued.
- 31 Aug 2023 Status changed from recruiting to suspended.
- 11 Jul 2022 New trial record